S'pore nurses, 36 & 34, seek S$2.4 million treatment for baby with rare genetic disorder
Two Singaporean nurses are raising S$2.4 million for their nine-month-old son Matthias, who has Spinal Muscular Atrophy, to access unsubsidised Zolgensma gene therapy before he turns one.
Intelligence analysis by Llama
Two Singapore nurses cannot afford the S$2.4 million Zolgensma gene therapy their nine-month-old son needs. Diagnosed with Type 2 SMA, Baby Matthias must receive the one-time treatment before his first birthday or risk irreversible motor neuron damage. The family has launched a public fundraiser, the third such SMA appeal in Singapore in recent years.
Baby Matthias has a disease that makes his muscles weaker every day. There is a special one-time medicine that could fix it, but it costs S$2.4 million, far more than his nurse parents could ever save. So they are asking the kind people of Singapore to help pay for it before he turns one.
Analysis
A Race Against 12 Months
Baby Matthias has a deadline that no negotiation can extend. Doctors have told his parents that the one-time Zolgensma infusion must be administered before he turns 12 months old. The reason is neurological: SMA destroys motor neurons progressively, and every week without the gene therapy means neurons lost that, according to the parents, are likely irreversible. At nine months, Matthias is already regressing in ways the family can see — he can no longer prop himself on his elbows, a milestone he had reached just weeks earlier. His parents have watched the window narrow in real time, which is why the urgency in the article is not abstract but biological.
The S$2.4 Million Question
Zolgensma is priced at S$2.4 million for a single dose, and Singapore does not subsidise it. The government does subsidise Risdiplam, the daily oral medication Matthias is currently taking, but that drug slows rather than stops the disease. The cost gap between the maintenance therapy and the curative one-shot is what has pushed two full-time nurses — one at the National Centre for Infectious Diseases, the other at Tan Tock Seng Hospital — to launch a public fundraiser. Their own calculation, that even selling their home and giving up essentials for five to eight years would not cover the bill, frames the story as a question about how Singaporean families are expected to access the most expensive drugs in modern medicine when they fall outside formal financial assistance.
The Third SMA Baby in the Headlines
Matthias is the third Singapore infant whose SMA diagnosis has been profiled by Mothership, after babies Ginny and Faziq. The doctors treating the family have flagged a real concern: donor fatigue. Each new case asks the public for sums that would fund a condominium, and the cumulative ask is testing the limits of community generosity. The family's response has been to lean on what they call a "village" — bosses allowing time off, grandparents handling daily physiotherapy, colleagues stepping in — but the actual village that needs to fund Zolgensma is, by definition, the wider public. Whether that village has the appetite to rally a third time is the open question hanging over the campaign, and one with implications well beyond this single household.
Key points
- Nine-month-old Baby Matthias was diagnosed with Type 2 Spinal Muscular Atrophy on Jul. 13 after losing the ability to prop himself on his elbows
- Zolgensma, a one-time gene therapy that can halt SMA progression, costs S$2.4 million and is not subsidised by the Singapore government
- Doctors have told the family the treatment must be administered before Matthias turns 12 months old or risk irreversible motor neuron loss
- Both parents are full-time nurses, at the National Centre for Infectious Diseases and Tan Tock Seng Hospital respectively
- This is the third such SMA infant case publicised in Singapore, and doctors have warned the family about potential donor fatigue
If the fundraiser reaches its target in time, Matthias could receive Zolgensma before his first birthday and halt the disease's progression, giving him a chance to grow with significantly better mobility. The family's existing network of colleagues, extended family, and a public primed by previous SMA campaigns has already begun mobilising, suggesting the appeal may resonate quickly.
Doctors have warned the family that donor fatigue, after two prior high-profile SMA fundraisers in Singapore, could blunt the response and slow donations. If the S$2.4 million is not raised before Matthias turns 12 months, the window for the one-time gene therapy closes, and the irreversible motor neuron damage already accumulating will permanently limit his mobility regardless of later treatment.
